Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Mar Drugs ; 22(6)2024 Jun 05.
Article in English | MEDLINE | ID: mdl-38921571

ABSTRACT

TRAF6 is an E3 ubiquitin ligase that plays a crucial role in cell signaling. It is known that MMP is involved in tumor metastasis, and TRAF6 induces MMP-9 expression by binding to BSG. However, inhibiting TRAF6's ubiquitinase activity without disrupting the RING domain is a challenge that requires further research. To address this, we conducted computer-based drug screening to identify potential TRAF6 inhibitors. Using a ligand-receptor complex pharmacophore based on the inhibitor EGCG, known for its anti-tumor properties, we screened 52,765 marine compounds. After the molecular docking of 405 molecules with TRAF6, six compounds were selected for further analysis. By replacing fragments of non-binding compounds and conducting second docking, we identified two promising molecules, CMNPD9212-16 and CMNPD12791-8, with strong binding activity and favorable pharmacological properties. ADME and toxicity predictions confirmed their potential as TRAF6 inhibitors. Molecular dynamics simulations showed that CMNPD12791-8 maintained a stable structure with the target protein, comparable to EGCG. Therefore, CMNPD12791-8 holds promise as a potential inhibitor of TRAF6 for inhibiting tumor growth and metastasis.


Subject(s)
Molecular Docking Simulation , Molecular Dynamics Simulation , TNF Receptor-Associated Factor 6 , Humans , TNF Receptor-Associated Factor 6/antagonists & inhibitors , TNF Receptor-Associated Factor 6/metabolism , Aquatic Organisms , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemistry , Drug Evaluation, Preclinical/methods , Catechin/analogs & derivatives , Catechin/pharmacology , Catechin/chemistry , Pharmacophore , Intracellular Signaling Peptides and Proteins
SELECTION OF CITATIONS
SEARCH DETAIL